Investment
Features
FeesSafety
Academy
More
Pluang+

Aeluma's Q4 revenue drops 56% as it shifts focus to AI datacom commercialization.

Company Fundamentals
18 Sep 2026
Seeking Alpha
View Source
Bearish
Aeluma's Q4 revenue drops 56% as it shifts focus to AI datacom commercialization.

Aeluma reported a 56% decline in Q4 revenue to $582,000 due to a strategic shift from government R&D to commercial AI datacom opportunities. The company is negotiating multimillion-dollar AI datacom projects that could validate customer interest turning into commercial programs. With $56 million cash and minimal debt at the end of FY2026, Aeluma has financial stability to support its commercialization efforts. However, FY2027 capital expenditures are expected to rise to $10-$12 million as manufacturing expands ahead of customer qualification and product revenue growth, leading to a downgrade to speculative buy due to financial weakness and commercialization uncertainty.

Aeluma's earnings and strategic shift provide context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Sep 18, 2026 21:31 WIB: out of 150 priced US technology stocks, 36 rose and 113 fell. Notable movers include RGTI at USD 15.26 with a 1-day change of -4.57% and a typical hold time of 31 days, EXFY at USD 2.24 down 4.27% with a 40-day hold, and VNET at USD 6.35 up 4.27% with a 15-day hold and 100% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App